Your Messages Inbox
Your Article Summary
See Latest ArticlesNovartis gains exclusive worldwide rights to PTK 0796, in Phase III study as potential first-in-class IV and oral broad-spectrum antibiotic
Novartis, 10/09/09
Novartis has gained exclusive worldwide rights to market PTK 0796, potentially the first once–daily broad–spectrum antibiotic that can be given by intravenous infusion or oral tablet to treat a wide variety of life–threatening infections, including those caused by highly resistant bacteria such as methicillin–resistant Staphylococcus aureus and multi–drug resistant Streptococcus pneumoniae.
Today in Medical Devices/Products...keeping you current
Receive free subspecialty "5-minute updates" via email
Chugai Revises Corporate Advertisement for First Time in Four Years
Chugai Pharmaceutical Co., 11/25/09
Huntington Hill Installs Toshiba Aquilion Premium CT
Imaging Economics, 11/25/09
Baytubes carbon nanotubes in marine coatings help reduce frictional resistance
BayNews International, 11/24/09
Today in Research & Development...keeping you current
Receive free subspecialty "5-minute updates" via email
Novartis inaugurates large-scale US based cell-culture influenza vaccine manufacturing facility
Novartis, 11/25/09
Bayer CropScience signs Agreement with GVK Biosciences on early-stage research projects
BayNews International, 11/25/09
Reports Rate Ambulatory EHR Software
HealthDataManagement, 11/25/09
Article Search
Sponsor